Mirum Pharmaceuticals announced Monday that its experimental hepatitis D treatment, brelovitug, met the primary endpoint in a late‑stage clinical trial. The drug, a monoclonal antibody designed to bind the hepatitis B surface antigen, was tested in patients already infected with chronic hepatitis B who also carry the hepatitis D virus.
Study results show promising viral reduction
At the 24‑week mark, 56% of participants receiving a 300‑milligram dose of brelovitug achieved a reduction in hepatitis D virus levels along with normal liver enzyme readings. An additional 45% of patients given a higher 900‑milligram dose reached the same outcomes. By contrast, none of the participants in the delayed‑treatment control group showed these improvements.
Safety profile aligns with earlier data
Across both dosage groups, brelovitug was well tolerated. The safety findings were consistent with the drug’s previously reported data, indicating no new safety concerns emerged during the trial.
Implications for patients and next steps
Chronic hepatitis D is a serious liver infection that can lead to severe liver damage and death. Mirum estimates the condition affects roughly 230,000 individuals in the United States and Europe. The trial’s positive results offer hope for a disease that currently has limited treatment options.
Full study details will be presented at an upcoming medical congress, and Mirum plans to submit a marketing application to the U.S. Food and Drug Administration in the first half of 2027.
About Mirum Pharmaceuticals
Mirum is a biopharmaceutical company focused on developing innovative therapies for liver‑related diseases. The company’s pipeline includes several candidates targeting viral infections and liver fibrosis.
Original reporting: Appleton, WI News Feed (HLL/CB) — read the source article.
